Skip to main content
Premium Trial:

Request an Annual Quote

NCI to Grant Around $11M for Cancer Molecular Analysis Technologies

NEW YORK (GenomeWeb News) – The National Institutes of Health said late last week it will support a number of new grants intended to push cancer-related molecular technologies through the National Cancer Institute under the NCI’s Innovative Molecular Analysis Technologies Program.
Applications for these grants are due on March 11, May 29, and Sept. 24, 2008. 
NCI will grant a total of $3 million to between 10 and 15 applicants for cancer molecular analysis tools. Applicants can request up to $500,000 over a three-year period. These grants would support tools that could be used to develop profiling technologies for DNA, RNA, proteins, and other biomolecules. 
NCI will grant a total of $1.5 million to fund between 10 and 15 grants for research that will evaluate the performance of new molecular analysis technologies and will focus on the application, rather than development, of these technologies.
NCI also will use $1.5 million to support four or five grants for cancer-relevant biological systems and molecular analysis emerging technologies, and applicants may apply for up to three years of funding. The research should focus on applications for the tools or methods and could include in vitro, in vivo, or in situ technologies.
Another NCI grant will offer up to $500,000 in fiscal 2009 for up to five programs to develop and/or study the application of technologies for sample preparation, purification, processing, and handling. Applicants may apply for funding over two years. The technologies involved could include tools, techniques, tools, instruments and devices, but not software or informatics solutions.
The NCI also will grant around $500,000 in the coming year for up to three other grants for maximizing the quality and utility of biospecimens for molecular analyses of cancer cells. This FOA also will support development of methods and tools to assess sample quality and to preserve sample integrity and to establish criteria for verifying and assessing quality control.
The NCI plans to support between three and five Phase I and Phase II SBIR grants seeking to develop and eventually commercialize molecular analysis technologies with around $1.3 million. Applicants may seek up to $100,000 a year for a total of two years for Phase I programs, while Phase II applicants can request up to $750,000 per year up to three years.
Another program will use the R41/R42 grant mechanism to fund Phases I, II, or III and Phase I and II Fast-Track applications with a total of $1.3 million for molecular analysis technologies. The NCI will support between three and five small businesses with up to $100,000 per year for up to two years for Phase I research, and a total of $750,000 for up to three years for Phase II research.  
A related program will grant up to nearly $1.3 million for between three and five SBIR grants with budgets up to $100,000 per year for up to two years. This grant will also will be aimed at supporting research into technologies to be used in the preparation, purification, processing, and handling of cancer-relevant samples.
The NCI also will support cancer-related sample technology development with approximately $1.3 million over one year for between three and five Phase I and Phase II SBIR technology development programs.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.